evidence/gaps
Cochrane · systematic review · CD013757

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children

Garegnani, L, Styrmisdóttir, L, Roson Rodriguez, P, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library

Acute Respiratory InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 3 · 50%High 2 · 33.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Palivizumab compared to placebo, no intervention or standard care for preventing respiratory syncytial virus (RSV) infection in children

Population: children (0 to 24 months)
6 questions
OutcomeEffectEvidenceStatus / GRADE
Hospitalisation due to RSV infection
Palivizumab vs placebo, no intervention or standard care
RR 0.44 [0.3, 0.64]5 studies · 3343 participantsHigh
Mortality
Palivizumab vs placebo, no intervention or standard care
RR 0.69 [0.42, 1.15]5 studies · 3343 participantsModerate
Downgraded: imprecision
Adverse events
Palivizumab vs placebo, no intervention or standard care
RR 1.09 [0.85, 1.39]3 studies · 2831 participantsModerate
Downgraded: imprecision
Hospitalisation due to respiratory‐related illness
Palivizumab vs placebo, no intervention or standard care
RR 0.78 [0.62, 0.97]5 studies · 3343 participantsModerate
Downgraded: imprecision
RSV infection
Palivizumab vs placebo, no intervention or standard care
RR 0.33 [0.2, 0.55]3 studies · 554 participantsLow
Number of wheezing days
Palivizumab vs placebo, no intervention or standard care
RR 0.39 [0.35, 0.44]1 study · 429 participantsHigh